Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 919 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: No intervention (observational study) Clear all
Terminated No phase listed Observational

B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease

NCT02316691
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 22, 2026, 1:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

DOAC ADRs Retrospective Study on Genetic Variations

NCT04580589
View directory record Official record
Conditions
Drug-Related Side Effects and Adverse Reactions, Treatment Failure
Interventions
Not listed
Lead sponsor
Cipherome, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 22, 2026, 1:08 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Whole Blood Specimen Collection From Pregnant Subjects

NCT02430584
View directory record Official record
Conditions
Down Syndrome, Edwards Syndrome, Patau Syndrome, Klinefelter Syndrome, Turner Syndrome, DiGeorge Syndrome, Perinatal Infections
Interventions
Observational - no intervention
Other
Lead sponsor
Progenity, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 22, 2026, 1:08 PM EDT
Recruiting No phase listed Observational

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

NCT04517838
View directory record Official record
Conditions
Breast Adenocarcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Interventions
Biospecimen Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 22, 2026, 1:08 PM EDT
Recruiting No phase listed Observational

A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

NCT06952426
View directory record Official record
Conditions
Immunoglobulin A Nephropathy
Interventions
No intervention, Other treatment, Iptacopan, Atrasentan
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 22, 2026, 1:08 PM EDT
Completed No phase listed Observational

Retrospective Study of Glucose Monitoring for Glycemic Control in Patients With GSDIa

NCT04708015
View directory record Official record
Conditions
Glycogen Storage Disease Type IA
Interventions
No Intervention
Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
8 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 22, 2026, 1:08 PM EDT
Completed Phase 1 Interventional

Glucocorticoid Administration After Traumatic Birth

NCT04852458
View directory record Official record
Conditions
Traumatic Birth
Interventions
Intravenous (IV) hydrocortisone
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 22, 2026, 1:08 PM EDT
Terminated No phase listed Observational

COVID Cohort Study

NCT04393155
View directory record Official record
Conditions
COVID-19, Acute Respiratory Failure
Interventions
COVID-19+ observational
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 22, 2026, 1:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of a Novel Human In Vitro Sarcoidosis Model

NCT01857401
View directory record Official record
Conditions
Sarcoidosis
Interventions
No intervention, observational study only
Other
Lead sponsor
Elliott Crouser MD
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 22, 2026, 1:08 PM EDT
Completed No phase listed Observational

A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan

NCT04113551
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
MPH (Concerta), MPH (Ritalin), Atomoxetine (ATO), Guanfacine (GFC)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
17,418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 22, 2026, 1:08 PM EDT
Recruiting No phase listed Observational

Undifferentiated Connective Tissue Disease Registry

NCT02234388
View directory record Official record
Conditions
Undifferentiated Connective Tissue Disease
Interventions
Observation
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 22, 2026, 1:08 PM EDT
Terminated No phase listed Observational

PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency

NCT06302439
View directory record Official record
Conditions
Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency, ATP-Binding Cassette Subfamily C Member 6 Deficiency
Interventions
No Intervention for this observational study
Other
Lead sponsor
Inozyme Pharma
Industry
Eligibility
Not listed
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 1:08 PM EDT
Not yet recruiting Not applicable Interventional

Intraosseous Antibiotics for Osseointegration

NCT07621094
View directory record Official record
Conditions
Osseointegration Infection
Interventions
intraosseous antibiotic delivery
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Aurora, Colorado • New York, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 1:08 PM EDT
Recruiting No phase listed Observational

Puberty, Testosterone, and Brain Development

NCT06670053
View directory record Official record
Conditions
Gender Identity, Gender Dysphoria in Adolescents and Adults, Headache, Transgender
Interventions
Testosterone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 20 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 22, 2026, 1:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Multi-omic Approach to Evaluate and Characterize the Polycystic Ovary Syndrome (PCOS) Phenotype

NCT04981275
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
No intervention study
Other
Lead sponsor
Onegevity Health
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 22, 2026, 1:08 PM EDT
Terminated Phase 2 Interventional Results available

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV

NCT00090779
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine/ tenofovir disoproxil fumarate, Lopinavir/Ritonavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
25
States / cities
San Diego, California • San Francisco, California • Torrance, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 22, 2026, 1:08 PM EDT
Completed Phase 3 Interventional Results available

Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

NCT01946412
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Birmingham, Alabama • Denver, Colorado • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 22, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

NCT05063539
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3372689, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
35
States / cities
Canoga Park, California • Fresno, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 22, 2026, 1:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Brain Characteristics Noted Prior to and Following Treatment

NCT02392195
View directory record Official record
Conditions
Nonsynostotic Plagiocephaly
Interventions
Non-interventional
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 8 Months
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 22, 2026, 1:08 PM EDT
Completed Not applicable Interventional

Shared Decision Making in Graves Disease - Graves Disease (GD) Choice

NCT02107794
View directory record Official record
Conditions
Graves' Disease, Thyroid Disease, Hyperthyroidism
Interventions
Decision Aid
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 22, 2026, 1:08 PM EDT
Recruiting No phase listed Observational

The KidneyCARE (Community Access to Research Equity) Study

NCT05497518
View directory record Official record
Conditions
Chronic Kidney Disease, Dialysis, Kidney Transplant
Interventions
Observational study - registry
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2070
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 22, 2026, 1:08 PM EDT
Recruiting Early Phase 1 Interventional

Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease

NCT07025226
View directory record Official record
Conditions
Glioma
Interventions
Biospecimen Collection, Dasatinib, Fisetin, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Quercetin, Temozolomide, Topoisomerase-1 Inhibitor LMP744, Single Agent Therapy
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 1:08 PM EDT
Enrolling by invitation No phase listed Observational

Long-Term Follow Up of VOY-101 Non-nAMD Extension Study

NCT07660640
View directory record Official record
Conditions
Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
Interventions
observational study, VOY-101
Other · Biological
Lead sponsor
Perceive Biotherapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Boston, Massachusetts • Bellaire, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 22, 2026, 1:08 PM EDT
Terminated Phase 3 Interventional Results available

Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

NCT00322218
View directory record Official record
Conditions
Lymphoma, Large Cell, Diffuse
Interventions
Zevalin
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
60 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 22, 2026, 1:08 PM EDT